Alzheimer’s Blood Test vs PET Scan vs Spinal Tap: Accuracy and Access Compared
Blood biomarkers improve convenience, but PET and spinal-fluid testing still resolve uncertain or treatment-sensitive cases.
Category Alzheimer’s
Why the Alzheimer’s Blood Test Is Not a Stand-Alone Diagnosis
A biomarker can reveal Alzheimer's-related biology without proving what is causing a person's cognitive symptoms.
Who Is the FDA-Cleared Alzheimer’s Blood Test Intended For?
Two cleared blood tests serve different ages and stages of cognitive evaluation, with important limits on screening and diagnosis.
Lumipulse Alzheimer’s Blood Test Accuracy: Positive, Negative, and Indeterminate Results
Learn what each Lumipulse result range can—and cannot—reveal about amyloid pathology and cognitive decline.
p-Tau217 Alzheimer’s Blood Tests: What Patients Should Know in 2026
A p-tau217 result can clarify amyloid status, but assay choice, clinical context, and a current reagent recall all matter.
Alzheimer’s in Every State: How to Find Your 2026 State Facts
A state-by-state guide to reading Alzheimer's mortality, caregiving, Medicaid, and treatment data with the right dates and definitions.
Why Women Have a Higher Lifetime Risk of Alzheimer’s Than Men
Women's Alzheimer's risk reflects a complex intersection of aging, hormones, genes, vascular health, and life experience.
What Is Your Lifetime Risk of Alzheimer’s Disease at Age 45?
Midlife Alzheimer's risk is shaped by longevity, health, family history, and the limits of population-based estimates.
How Much Do Families Pay Out of Pocket for Alzheimer’s and Dementia Care?
Dementia's true price includes supervision, lost income, housing, safety changes, and services that health insurance often excludes.
At-Home Leqembi for Alzheimer’s Is FDA-Approved but Not for Everyone
Home dosing may ease travel, but Leqembi still demands careful eligibility screening, MRI surveillance, and informed risk decisions.